

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

8505C

RRID:CVCL_1054

Type: Cell Line

Proper Citation

RRID:CVCL_1054

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1054

Proper Citation: RRID:CVCL_1054

Description: Cell line 8505C is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: [PMID:1516062](#), [PMID:9247707](#), [PMID:9290701](#), [PMID:14522906](#), [PMID:15613457](#), [PMID:16924234](#), [PMID:17725429](#), [PMID:17804723](#), [PMID:18713817](#), [PMID:19087340](#), [PMID:20164919](#), [PMID:21566963](#), [PMID:21868764](#), [PMID:22460905](#), [PMID:23162534](#), [PMID:23833040](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30737244](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 8505C

Synonyms: 8505c

Cross References: BTO:BTO_0005550, CLO:CLO_0001513, CLO:CLO_0050951, EFO:EFO_0022669, CLDB:cl135, CLDB:cl136, AddexBio:C0025002/19, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BCRJ:0398, BioSample:SAMN01821611, BioSample:SAMN03470935, BioSample:SAMN03472518,

BioSample:SAMN03473379, BioSample:SAMN10988556, cancercellines:CVCL_1054, Cell_Model_Passport:SIDM00996, CGH-DB:54-1, ChEMBL-Cells:ChEMBL3308353, ChEMBL-Targets:ChEMBL1075387, Cosmic:889489, Cosmic:891256, Cosmic:922365, Cosmic:924102, Cosmic:1084283, Cosmic:1132598, Cosmic:1152114, Cosmic:1162837, Cosmic:1239959, Cosmic:2036694, Cosmic:2054105, Cosmic:2613248, Cosmic-CLP:924102, DepMap:ACH-001307, DSMZ:ACC-219, DSMZCellDive:ACC-219, ECACC:94090184, EGA:EGAS00001000978, FANTOM5_SSTAR:10437-106E5, GDSC:924102, GEO:GSM886847, GEO:GSM887911, GEO:GSM1669574, IARC_TP53:1305, JCRB:JCRB0826, LiGeA:CCE_065, LINCS_LDP:LCL-1686, PharmacDB:8505C_31_2019, PRIDE:PXD030304, Progenetix:CVCL_1054, PubChem_Cell_line:CVCL_1054, RCB:RCB2103, TKG:TKG 0439, Wikidata:Q54605341

ID: CVCL_1054

Record Creation Time: 20220427T215101+0000

Record Last Update: 20260904T021126+0000

Ratings and Alerts

No rating or validation information has been found for 8505C.

No alerts have been found for 8505C.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bó IFD, et al. (2026) Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. Journal of applied toxicology : JAT.

Dal' Bó IF, et al. (2026) Roundup® Original DI promotes proliferation in papillary thyroid carcinoma cells: a comparative study highlighting cell-type-dependent effects. Frontiers in endocrinology, 17, 1745247.

Lu B, et al. (2026) Rational Inhibitor Discovery for BRAFV600E Using PSeMut, a Sequence-Driven Model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(13), e72118.

Kellett MD, et al. (2025) Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. Frontiers in oncology, 15, 1252544.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Lim G, et al. (2025) AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. *iScience*, 28(8), 113194.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. *The Journal of clinical endocrinology and metabolism*, 110(4), 991.

Zielinski JM, et al. (2025) Thyroid Hormone Receptor α Suppresses Cancer Cell Activity by Differential Regulation of Glycogen Metabolism. *Endocrinology*, 166(12).

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Hicks HM, et al. (2023) Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. *Molecular cancer research : MCR*, 21(9), 867.

Read ML, et al. (2022) Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter. *Cell chemical biology*, 29(3), 502.

Li Y, et al. (2022) NCOA3 is a critical oncogene in thyroid cancer via the modulation of major signaling pathways. *Endocrine*, 75(1), 149.

So?tys A, et al. (2021) Relationship between Maturity Stage, Triterpenoid Content and Cytotoxicity of *Sorbus intermedia* (EHRH.) PERS. *Fruits - A Chemometric Approach. Chemistry & biodiversity*, 18(11), e2100552.

Henderson YC, et al. (2021) A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. *The Journal of clinical endocrinology and metabolism*, 106(10), 2962.

Grabowska K, et al. (2021) Serjanic Acid Glycosides from *Chenopodium hybridum* L. with Good Cytotoxicity and Selectivity Profile against Several Panels of Human Cancer Cell Lines. *Molecules (Basel, Switzerland)*, 26(16).

Zhang Q, et al. (2021) Hsa_circ_0023990 Promotes Tumor Growth and Glycolysis in Dedifferentiated TC via Targeting miR-485-5p/FOXO1 Axis. *Endocrinology*, 162(12).

O'Connell TJ, et al. (2021) Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer. *Frontiers in cell and developmental biology*, 9, 663130.

Montero-Conde C, et al. (2020) Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing. *International journal of cancer*, 146(2), 521.